NCT05355311已完成1 期
L-carnitine Supplementation for Co-occurring Depression and Alcohol Use Disorder in Youth: An Open Trial Pilot Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Alcohol Craving (derived from the Alcohol Urge Questionnaire; 0 to 20; higher scores = greater urge to drink)
研究概览
简要总结
The primary objective of this study is to evaluate the effects of L-carnitine, 2.97g daily on alcohol cue-elicited alcohol craving during a human laboratory paradigm after 4 weeks of daily dosing among participants ages 18-25 with alcohol use disorder (AUD) as confirmed by the Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5™) and who report at least mild depressive symptoms on the Beck Depression Inventory-II. Secondary objectives include evaluation of L-carnitine (2.97g/day) on alcohol craving and use, subjective effects of alcohol consumption, mood, sleep, alcohol use negative consequences, study retention, and safety and tolerability.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 25 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be 18 to 25 years old, inclusive
- •Self-report consuming alcohol ≥ 2 days/week on average in the past 28 days
- •Meets the DSM-5 criteria for alcohol use disorder (AUD)
- •Be interested in reducing alcohol use
- •Report at least mild depressive symptoms, as indicated by a score ≥ 14 on the Beck Depression Inventory II.
- •Be able to verbalize an understanding of the consent/assent form, able to provide written informed consent/assent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English and able to complete the questionnaires required by the protocol.
- •Have parent permission, if younger than 18 years
- •Be able to take oral medication and be willing to adhere to the medication regimen
- •Complete all assessments required at screening and baseline.
- •Provide contact information of someone, such as a parent or other family member, who may be able to contact the subject in case of a missed appointment or follow-up assessment.
- •Agree to the schedule of visits, verbally acknowledge ability to attend each scheduled visit, participate in phone visits and report no scheduled events or a job that may substantially interfere with study participation.
- •Not anticipate any significant problems with transportation arrangements or available time to travel to the study site over the next 2 months.
- •Agree (if the subject's sex is female and of childbearing potential) to use at least one reliable method of birth control, unless subject is surgically sterile, partner is surgically sterile, or subject is postmenopausal. Examples of reliable methods include (but may not be limited to):
- •oral contraceptives
- •contraceptive sponge
- •contraceptive skin patch
- •double barrier diaphragm (diaphragm/spermicidal or condom/spermicidal)
- •intrauterine contraceptive system
- •levonorgestrel implant
- •medroxyprogesterone acetate contraceptive injection
- •complete abstinence from sexual intercourse
- •hormonal vaginal contraceptive ring
排除标准
- •Be currently receiving alcohol use disorder treatment
- •Have significant alcohol withdrawal symptoms (score > 10) on the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-AR)
- •Have a coexisting moderate to severe substance use disorder other than cannabis and nicotine, as defined by DSM-5 criteria
- •Have a urine toxicology screen positive performed during screening or baseline for any of the following substances:
- •benzodiazepines
- •amphetamines
- •buprenorphine
- •barbiturates
- •3, 4-methylenedioxy-methamphetamine (MDMA, also known as ecstasy)
- •methamphetamines
- •Have been treated with a pharmacotherapy for alcohol use disorder or a carbonic anhydrase inhibitor within 30 days prior to randomization
- •Compelled to alcohol treatment by the juvenile justice system or has probation or parole requirements that might interfere with study participation
- •Have a history of liver disease or have clinically significant abnormal laboratory values, including elevation of liver enzymes (AST, ALT) 5-fold above the upper limit of normal (ULN), or bilirubin greater than 2 times the upper limit of normal.
- •History of renal impairment or renal stones, heart problems or defects, abnormal blood pressure, progressive neurodegenerative disorder, or clinically significant neurological disorders
- •Clinically significant physical abnormalities per physical exam, hematological assessment, bilirubin concentration, or urinalysis
- •Pregnancy, nursing, or refusal to use reliable birth control, if female of childbearing potential
- •Stable dose of any prescribed psychotropic medication (i.e., no dose changes in the 2 months prior to randomization)
- •Current or lifetime diagnosis of psychotic disorders or current bipolar disorder
- •Current suicidality risk
- •Known sensitivity to acetyl-l-carnitine
- •Be a subject who in the opinion of the investigator could not be safely withdrawn from alcohol without medical detoxification
- •Have a serious or unstable medical illness or any potentially life-threatening or progressive medical condition other than addiction that may compromise subject safety or study conduct
- •Have abnormal calculated creatinine clearance defined as < 80 mL/min
- •Have data suggesting cirrhosis of the liver (albumin < 3.2 g/dL, or ascites by physical exam)
研究组 & 干预措施
L-Carnitine
Experimental
L-carnitine is a nutritional supplement and emerging research shows it has neuroprotective properties and may help treat alcohol use disorder and depression, 2.97 g daily for 6 weeks
干预措施: L-carnitine (Drug)
结局指标
主要结局
Alcohol Craving (derived from the Alcohol Urge Questionnaire; 0 to 20; higher scores = greater urge to drink)
时间窗: Week 5
Strength of self-reported alcohol craving
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
L-carnitine Supplementation in Rheumatoid Arthritis PatientsRheumatoid Arthritis (RA)NCT06753565German University in Cairo60
已完成
2 期
Propionyl-L-Carnitine in Ulcerative ColitisUlcerative ColitisNCT01026857sigma-tau i.f.r. S.p.A.121
已完成
不适用
The L-carnitine effect in non alcoholic fatty livernon alcoholic fatty liver disease.Fatty (change of) liver, not elsewhere classifiedIRCT201102235893N1Gasrtoenterology Research Centre Of Imam Reza Hospital80
已完成
不适用
carnitine effect in diabetic fatty liver diseasenon alcoholic fatty liver disease.Other specified inflammatory liver diseasesIRCT2014020316348N2Gastroentrology Recerch Center, Ahwaz Jundishapur Medical School30
已完成
不适用
Investigation on the Effect of Carnitine Supplement on Gut Microbiota and TMAO Production CapacityDietary ExposureNCT02838732National Taiwan University Hospital56